Pacific Biosciences of California Inc. (PACB)
PACB trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1299130/000129913026000034/0001299130-26-000034-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PACB on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2010 |
| SEC CIK | 0001299130 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $160.0M |
| Net income | -$546.4M |
| Operating income | -$553.9M |
| Net margin | -341.5% |
| Operating margin | -346.2% |
| Revenue growth | +3.9% |
| Cash | $63.7M |
| Total assets | $784.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $55.9M cash; operating cash flow -$34.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 312,926,730 (2026-10-31); 301,907,431 a year earlier; 267,443,887 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-11-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $40.6M | -$37.8M | -$37.6M | $55.9M | No debt tags | $161.4M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $39.0M | -$44.7M | -$35.6M | $61.0M | No debt tags | $159.3M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $37.2M | -$8.3M | -$44.7M | $56.3M | No debt tags | $160.0M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $44.6M | -$40.4M | -$19.1M | $63.7M | No debt tags | $160.0M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $38.4M | -$38.0M | -$18.7M | $56.5M | No debt tags | $154.6M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $39.8M | -$41.9M | -$29.4M | $54.8M | No debt tags | $156.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $37.2M | -$426.1M | -$44.1M | $58.5M | No debt tags | $152.4M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $39.2M | $2.4M | -$30.6M | $55.4M | $0 | $154.0M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-10 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-05-22 |
Source: SEC EDGAR submissions feed, 977 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.3% |
| 1 month | -4.4% |
| 3 months | +70.4% |
| Year to date | +4.8% |
| 1 year | +20.2% |
| From 52-week high | -32.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CTKB | Cytek Biosciences Inc. | $5.63 | -3.60% | $736.3M |
| NAUT | Nautilus Biotechnology Inc. | $2.10 | -9.48% | $267.5M |
| LAB | Standard BioTools Inc. | $0.6210 | -12.21% | $245.2M |
| ALMR | Alamar Biosciences Inc. | $30.55 | -0.84% | $2.1B |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| TXG | 10x Genomics Inc. | $54.99 | -5.50% | $7.2B |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier